Bayer’s Summer of Reckoning: Supreme Court, Settlement Hearing, and a US Trade Probe Collide
20.06.2026 - 10:32:22 | boerse-global.de
Bayer’s stock ended last week nearly flat on the year but sitting exactly on its 50-day moving average — a technical stalemate that belies the storm of legal, regulatory, and operational events gathering around the German pharmaceutical and crop-science group. The shares closed Friday at €37.81, a weekly gain of 4.85%, as investors parsed a flurry of headlines that could determine the company’s direction for years to come.
The most consequential of those headlines centres on the US Supreme Court. Bayer is pinning its hopes on the “preemption” argument in the Missouri case Durnell — the principle that federal pesticide labelling requirements, as enforced by the Environmental Protection Agency, should override state-level failure-to-warn claims. Chief Executive Bill Anderson has publicly stressed that companies cannot be penalised for complying with federal rules. A ruling in Bayer’s favour, analysts estimate, could eliminate up to 80% of the outstanding glyphosate litigation. The Supreme Court could deliver its decision as early as June 22, though some observers expect a ruling by the end of July.
Meanwhile, the company’s proposed multibillion-dollar settlement of the remaining Roundup claims is moving toward a finale of its own. On June 17, US District Judge Henry E. Autrey in Missouri handed Bayer a procedural victory by sending the class-action settlement King v. Monsanto back to state court, rejecting plaintiffs’ efforts to keep it in federal jurisdiction. The settlement, which aims to resolve nearly all of the roughly 65,000 still-open claims, received preliminary approval from Judge Timothy Boyer in March. The final fairness hearing is set for July 9 in St. Louis. Bayer has already allocated more than $10 billion to settle Roundup cases, and the company expects litigation cash outflows of roughly €5 billion in 2026 alone, pushing free cash flow as low as minus €2.5 billion.
Should investors sell immediately? Or is it worth buying Bayer?
A separate front opened in Washington on June 20, when the US government launched a Section 301 investigation into drug pricing in Germany. The probe alleges that American consumers shoulder a disproportionate share of pharmaceutical R&D costs because German prices for branded medicines are far lower. For Bayer, the long-term risks include margin pressure on US sales or even trade restrictions. The uncertainty is compounded by a delay in Germany’s planned healthcare reform, now postponed to July 10.
Amid the legal and regulatory turbulence, Bayer is pressing forward with its pipeline. The company this week completed the acquisition of Perfuse Therapeutics, paying $300 million upfront with milestone payments that could lift the total consideration to $2.45 billion. The deal’s centrepiece is PER-001, an intravitreal implant in Phase II trials targeting glaucoma and diabetic retinopathy — conditions affecting roughly 80 million and 146 million people globally, respectively. Bayer believes the therapy could become one of the first disease-modifying treatments for both indications.
On the operational side, Bayer’s SOLIDA-1 production facility in the Chempark Leverkusen won the “Facility of the Year Award” in two categories — Operational Excellence and Pharma 4.0. The company invested roughly €275 million in the plant, which uses artificial intelligence for process optimisation and geothermal energy to cut CO? emissions by about 70%. The goal is to accelerate the time-to-market for new drugs.
Analysts remain cautiously optimistic about the stock’s upside. UBS rates Bayer a “Buy” with a €52 price target, while Morgan Stanley sees potential to €53 — levels that would require a clear resolution of the legal overhangs. For now, the share price is locked in a neutral technical posture. The next decisive move will likely come not from the trading floor, but from a judge’s gavel — first in St. Louis on July 9, and then from the Supreme Court in the weeks that follow.
Ad
Bayer Stock: New Analysis - 20 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
